CXCR1 and head and neck cancer: Another strategy for eliminating NK cell-suppressive activity of MDSCs is based on inhibiting MDSC trafficking with SX-682, a CXCR1/2 inhibitor; this can be used to enhance NK cell immunotherapy in head and neck cancer models [483].